TXG — 10x Genomics, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1770787 ·
Last close
$56.30
Market Cap
$6.77B
52W High
$102.81
52W Low
$15.18
ADV30
3,613,747
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 150,667,000 | 112,927,000 | -16,057,000 | -19,425,000 | 1,063,129,000 | 526,187,000 | 225,093,000 |
| Jun 2026 | 151,036,000 | 112,497,000 | -22,955,000 | -17,931,000 | 1,030,066,000 | 502,512,000 | 204,520,000 |
| Mar 2026 | 150,843,000 | 106,178,000 | -17,046,000 | -13,470,000 | 1,015,759,000 | 490,285,000 | 201,435,000 |
| Dec 2025 | 166,030,000 | 113,045,000 | -19,541,000 | -16,252,000 | 1,041,365,000 | 473,966,000 | 245,039,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$127,085,000
Investing CF
$-19,652,000
Financing CF
$-2,542,000
CapEx
$-5,649,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.59
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,541,992,000
Inventory
$52,616,000
Receivables
$50,629,000
ST Investments
$49,521,000
EBIT TTM
$-16,496,000
Pretax Income TTM
$-74,890,000
Interest Exp TTM
$3,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$618,576,000
EBITDA
$-25,942,000
Free Cash Flow
$179,656,000
Enterprise Value
$7,254,282,240
Total Cash
$575,680,000
Total Debt
$75,792,000
Shares Out
120,212,296
Trailing EPS
$-0.52
Book Value
$6.41
ROE
-8.3%
ROA
-3.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 642,823,000 | -110,885,000 | -43,544,000 | 1,041,365,000 | 245,039,000 | 796,326,000 | 136,050,000 |
| Dec 2024 | 610,785,000 | -194,559,000 | -182,627,000 | 918,636,000 | 208,502,000 | 710,134,000 | 6,664,000 |
| Dec 2023 | 618,727,000 | -204,349,000 | -255,099,000 | 965,143,000 | 224,100,000 | 741,043,000 | -15,197,000 |
| Dec 2022 | 516,409,000 | -167,944,000 | -166,000,000 | 1,028,980,000 | 223,237,000 | 805,743,000 | -33,606,000 |
TTM Snapshot
Revenues TTM
$616,911,000
NetIncome TTM
$-75,125,000
OpCashFlow TTM
—
Assets (Latest)
$1,030,066,000
Forward EPS
$0.09
Max Pain — expiry 2027-02-19
max pain strike: $65.00 · spot: $57.07 · call oi: 2,247 · put oi: 1,133
Expected Move to 2027-02-19:
±$19.50
(34.17%) —
implied range
$37.57 –
$76.57
· ATM straddle on $55.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ESYJY | easyJet plc | $6.74B | $9.02 | — |
| SNHIY | Sany Heavy Industries Co., Ltd./ADR | $6.80B | $9.44 | — |
| LOTMY | Lottomatica Group S.p.A./ADR | $6.82B | $29.33 | — |
| VG | Venture Global, Inc. | $6.86B | $12.50 | — |
| CHDN | Churchill Downs Inc | $6.67B | $97.28 | — |
News headlines (Yahoo Finance, 1h cache)
10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations
2026-11-16 21:05 · Yahoo
10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study
2026-11-12 17:27 · Yahoo
What Makes 10x Genomics (TXG) a Strong Position Ahead of Its H2 2026 Atera Launch?
2026-11-12 16:42 · Yahoo
TXG Q3 2026 deep dive: spatial platform launch and AI-driven demand shape outlook
2026-11-10 09:57 · Yahoo
10x Genomics (TXG) Could Be 24% Undervalued After Raising Its 2026 Revenue Outlook
2026-11-07 11:11 · Yahoo
10x Genomics Inc (TXG) (Q3 2026) Earnings Call Highlights: Atera Launch Takes Flight as Revenue ...
2026-11-06 17:13 · Yahoo
10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis
2026-11-06 15:54 · Yahoo
What 10x Genomics (TXG) Said on Its Q3 Earnings Call
2026-11-06 14:14 · Yahoo
10x Genomics, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
10x Genomics (TXG) Q3 2026 Earnings Call Transcript
2026-11-06 08:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.